Paradigm Biocapital Advisors Portfolio
Hedge fund & macroParadigm Biocapital Advisors LP 13F holdings · Q3 2026 vs Q2 2026
Why hedge fund & macro: 28 holdings, 11 effective · top 10 75% · turnover 36% a quarter · earnings yield -5.3% (median 2.9%) · 20 quarters of 13Fs
- 13F value
- $5.0bn−5.8% vs $5.3bn in Q2 2026
- Holdings
- 29 7 new · 4 sold out
- Top 10 weight
- 77.6% Largest: RVMD 25.4%
- Bought est.
- $857m New positions and adds
- Sold est.
- $363m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| Added | INSMINSMED INC | +103.3% | +$156m | 2.6% → 6.1% | 7 |
| New | BBIOBRIDGEBIO PHARMA INC | New | +$154m | 0.0% → 3.1% | 3 |
| Sold out | ALNYALNYLAM PHARMACEUTICALS INC | −100.0% | −$144m | 2.7% → 0.0% | — |
| Added | MBXMBX BIOSCIENCES INC | +50.4% | +$74m | 2.6% → 4.4% | 3 |
| New | OBXOBSIDIAN THERAPEUTICS INC | New | +$57m | 0.0% → 1.1% | 4 |
| Added | SYRESPYRE THERAPEUTICS INC | +16.1% | +$55m | 6.4% → 7.9% | 3 |
| Added | JBIOJADE BIOSCIENCES INC | +111.8% | +$45m | 1.2% → 1.7% | 3 |
| Sold out | EYPTEYEPOINT INC | −100.0% | −$41m | 0.8% → 0.0% | — |
| New | GPCRSTRUCTURE THERAPEUTICS INC | New | +$41m | 0.0% → 0.8% | 5 |
| New | MANEVERADERMICS INC | New | +$38m | 0.0% → 0.7% | 2 |
| Trimmed | TARSTARSUS PHARMACEUTICALS INC | −17.1% | −$37m | 3.3% → 3.6% | 3 |
| Added | TYRATYRA BIOSCIENCES INC | +92.0% | +$37m | 1.1% → 1.5% | 5 |
| Added | GMABGENMAB A/S | +7.6% | +$36m | 6.8% → 10.0% | 1 |
| Added | VRDNVIRIDIAN THERAPEUTICS INC | +22.8% | +$32m | 2.3% → 3.4% | 6 |
| Trimmed | RVMDREVOLUTION MEDICINES INC | −2.2% | −$29m | 22.3% → 25.4% | 8 |
| Added | ORKAORUKA THERAPEUTICS INC | +16.3% | +$29m | 3.8% → 4.1% | 5 |
| Sold out | MPLTMAPLIGHT THERAPEUTICS INC | −100.0% | −$25m | 0.5% → 0.0% | — |
| Added | EWTXEDGEWISE THERAPEUTICS INC | +5.5% | +$23m | 7.8% → 8.7% | 4 |
| Trimmed | ERASERASCA INC | −16.2% | −$23m | 3.3% → 2.3% | 3 |
| New | ORICORIC PHARMACEUTICALS INC | New | +$20m | 0.0% → 0.4% | 1 |
| New | KRSAKORSANA BIOSCIENCES INC | New | +$20m | 0.0% → 0.4% | 5 |
| Sold out | LXEOLEXEO THERAPEUTICS INC | −100.0% | −$19m | 0.4% → 0.0% | — |
| New | COAGHEMAB THERAPEUTICS HLDGS INC | New | +$19m | 0.0% → 0.4% | 4 |
| Trimmed | VORVOR BIOPHARMA INC | −49.2% | −$16m | 0.6% → 0.3% | 4 |
| Trimmed | BLTEBELITE BIO INC | −7.4% | −$15m | 3.6% → 3.9% | 2 |
| Added | TNGXTANGO THERAPEUTICS INC | +9.5% | +$15m | 3.7% → 3.5% | 7 |
| Trimmed | IVAINVENTIVA SA | −79.8% | −$12m | 0.3% → 0.1% | 1 |
| Added | EDITEDITAS MEDICINE INC | +35.6% | +$5.1m | 0.3% → 0.4% | 2 |
| Added | PCVXVAXCYTE INC | +0.7% | +$854k | 2.3% → 2.4% | 3 |
| Added | OLMAOLEMA PHARMACEUTICALS INC | +0.6% | +$432k | 2.0% → 1.5% | 2 |
All holdings 29 identified, plus $3.8m in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INC | $1.3bn | 6,219,323 | −2.2% | 8 | |
| 2 | GMABGENMAB A/S | $504m | 14,136,472 | +7.6% | 1 | |
| 3 | EWTXEDGEWISE THERAPEUTICS INC | $438m | 10,778,665 | +5.5% | 4 | |
| 4 | SYRESPYRE THERAPEUTICS INC | $397m | 4,457,450 | +16.1% | 3 | |
| 5 | INSMINSMED INC | $308m | 2,695,977 | +103.3% | 7 | |
| 6 | MBXMBX BIOSCIENCES INC | $221m | 3,772,885 | +50.4% | 3 | |
| 7 | ORKAORUKA THERAPEUTICS INC | $208m | 2,493,507 | +16.3% | 5 | |
| 8 | BLTEBELITE BIO INC | $194m | 1,142,123 | −7.4% | 2 | |
| 9 | TARSTARSUS PHARMACEUTICALS INC | $181m | 2,301,375 | −17.1% | 3 | |
| 10 | TNGXTANGO THERAPEUTICS INC | $174m | 6,961,546 | +9.5% | 7 | |
| 11 | VRDNVIRIDIAN THERAPEUTICS INC | $170m | 8,257,672 | +22.8% | 6 | |
| 12 | BBIOBRIDGEBIO PHARMA INC | $154m | 2,347,850 | New | 3 | |
| 13 | PCVXVAXCYTE INC | $122m | 2,142,852 | +0.7% | 3 | |
| 14 | ERASERASCA INC | $117m | 7,998,257 | −16.2% | 3 | |
| 15 | JBIOJADE BIOSCIENCES INC | $85m | 6,053,268 | +111.8% | 3 | |
| 16 | TYRATYRA BIOSCIENCES INC | $77m | 3,510,360 | +92.0% | 5 | |
| 17 | OLMAOLEMA PHARMACEUTICALS INC | $75m | 8,720,576 | +0.6% | 2 | |
| 18 | OBXOBSIDIAN THERAPEUTICS INC | $57m | 4,155,214 | New | 4 | |
| 19 | GPCRSTRUCTURE THERAPEUTICS INC | $41m | 1,299,199 | New | 5 | |
| 20 | QUITACHIEVE LIFE SCIENCE INC | $40m | 4,951,856 | Unchanged | 4 | |
| 21 | MANEVERADERMICS INC | $38m | 310,060 | New | 2 | |
| 22 | ASMBASSEMBLY BIOSCIENCES INC | $36m | 1,553,748 | Unchanged | 2 | |
| 23 | ORICORIC PHARMACEUTICALS INC | $20m | 1,505,769 | New | 1 | |
| 24 | KRSAKORSANA BIOSCIENCES INC | $20m | 613,914 | New | 5 | |
| 25 | EDITEDITAS MEDICINE INC | $19m | 7,575,140 | +35.6% | 2 | |
| 26 | COAGHEMAB THERAPEUTICS HLDGS INC | $19m | 629,347 | New | 4 | |
| 27 | VORVOR BIOPHARMA INC | $17m | 889,575 | −49.2% | 4 | |
| 28 | KARDKARDIGAN INC | $13m | 900,000 | Unchanged | 1 | |
| 29 | IVAINVENTIVA SA | $3.0m | 808,176 | −79.8% | 1 |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- Rtw Investments21.3%11 shared · INSM, TNGX, SYRE, TARS
- Bvf20.5%5 shared · RVMD, TYRA, OLMA, GPCR
- Farallon Capital Management18.2%4 shared · RVMD, BBIO, TNGX, ASMB
- Novo Holdings17.2%6 shared · EWTX, PCVX, VRDN, INSM
- Baker Bros. Advisors16.2%7 shared · RVMD, INSM, EWTX, GPCR
- Perceptive Advisors13.9%9 shared · SYRE, EWTX, ORKA, RVMD
- Deerfield Management13.9%7 shared · RVMD, GMAB, TNGX, GPCR
- TCG Crossover Management13.7%9 shared · SYRE, TNGX, TYRA, MBX
- Ra Capital Management11.2%11 shared · EWTX, PCVX, TYRA, ORKA
- Fairmount Funds Management9.6%4 shared · ORKA, VRDN, JBIO, KRSA
Only here
The largest holdings no other tracked guru owns.
Every holding is shared with at least one other guru.
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed